Cargando…
Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults
Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammalian cell-based, MF59(®)-adjuvanted, A/H5N1 vaccine...
Autores principales: | Versage, Eve, van Twuijver, Esther, Jansen, Wim, Theeuwes, Ad, Sawlwin, Daphne, Hohenboken, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704792/ https://www.ncbi.nlm.nih.gov/pubmed/34960214 http://dx.doi.org/10.3390/vaccines9121468 |
Ejemplares similares
-
Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults
por: Frey, Sharon S., et al.
Publicado: (2023) -
Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects
por: Peterson, James, et al.
Publicado: (2022) -
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023) -
Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013) -
AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)